In a significant stride forward, a global phase 3 clinical trial, including the prestigious Ann & Robert H. Lurie Children’s Hospital of Chicago, has unveiled a groundbreaking finding. The year-long immunotherapy treatment using a skin patch has effectively desensitized toddlers with peanut allergies, substantially reducing the risk of severe allergic reactions caused by accidental exposure.
Published in the esteemed New England Journal of Medicine, the study funded by DBV Technologies brings renewed optimism. Children who once experienced adverse reactions to minute amounts of peanuts can now tolerate one to four peanuts, offering respite and protection against inadvertent exposure.
